LT2885010T - Tautopatijos gydymo būdai - Google Patents

Tautopatijos gydymo būdai

Info

Publication number
LT2885010T
LT2885010T LTEP13830020.7T LT13830020T LT2885010T LT 2885010 T LT2885010 T LT 2885010T LT 13830020 T LT13830020 T LT 13830020T LT 2885010 T LT2885010 T LT 2885010T
Authority
LT
Lithuania
Prior art keywords
tautopathy
treatment
methods
Prior art date
Application number
LTEP13830020.7T
Other languages
English (en)
Inventor
Irene Griswold-Prenner
Nancy E. Stagliano
Vu DANG
Original Assignee
Ipierian, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipierian, Inc. filed Critical Ipierian, Inc.
Publication of LT2885010T publication Critical patent/LT2885010T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
LTEP13830020.7T 2012-08-16 2013-08-15 Tautopatijos gydymo būdai LT2885010T (lt)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201261683902P 2012-08-16 2012-08-16
US201361754085P 2013-01-18 2013-01-18
US201361781823P 2013-03-14 2013-03-14
US201361813797P 2013-04-19 2013-04-19
US201361833355P 2013-06-10 2013-06-10
PCT/US2013/055203 WO2014028777A2 (en) 2012-08-16 2013-08-15 Methods of treating a tauopathy

Publications (1)

Publication Number Publication Date
LT2885010T true LT2885010T (lt) 2020-04-27

Family

ID=50101612

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP13830020.7T LT2885010T (lt) 2012-08-16 2013-08-15 Tautopatijos gydymo būdai

Country Status (32)

Country Link
US (6) US9567395B2 (lt)
EP (2) EP3685854A1 (lt)
JP (1) JP6290212B2 (lt)
KR (1) KR102076384B1 (lt)
CN (1) CN104736185B (lt)
AU (1) AU2013302540B2 (lt)
BR (1) BR112015003326A2 (lt)
CA (1) CA2882034C (lt)
CL (1) CL2015000352A1 (lt)
CY (1) CY1123515T1 (lt)
DK (1) DK2885010T3 (lt)
EA (2) EA035976B1 (lt)
ES (1) ES2775192T3 (lt)
GB (1) GB2507207A (lt)
HR (1) HRP20200036T1 (lt)
HU (1) HUE048780T2 (lt)
IL (1) IL237153B (lt)
LT (1) LT2885010T (lt)
ME (1) ME03667B (lt)
MX (1) MX359817B (lt)
MY (1) MY176838A (lt)
NZ (2) NZ630542A (lt)
PE (1) PE20150646A1 (lt)
PH (1) PH12015500196A1 (lt)
PL (1) PL2885010T3 (lt)
PT (1) PT2885010T (lt)
RS (1) RS60080B1 (lt)
SG (2) SG10201701181XA (lt)
SI (1) SI2885010T1 (lt)
SM (1) SMT202000180T1 (lt)
TN (1) TN2015000050A1 (lt)
WO (1) WO2014028777A2 (lt)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
EP2346906A4 (en) 2008-10-15 2013-04-24 Angiochem Inc CONJUGATES FROM GLP-1 AGONISTS AND THEIR USE
SG10201913370PA (en) 2012-07-03 2020-03-30 Univ Washington Antibodies to tau
SI2885010T1 (sl) 2012-08-16 2020-07-31 Ipierian, Inc. Metode zdravljenja tauopatije
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
CA2902026C (en) 2013-03-13 2023-08-29 Prothena Biosciences Limited Tau immunotherapy
EA039554B1 (ru) * 2013-06-10 2022-02-09 АйПИЕРИАН, ИНК. Способ снижения уровней a40 и/или a42 в нервной клетке и/или во внеклеточной жидкости
WO2015081085A2 (en) * 2013-11-27 2015-06-04 Ipierian, Inc. Methods of treating a tauopathy
AU2014368696A1 (en) 2013-12-20 2016-06-02 F. Hoffmann-La Roche Ag Humanized anti-Tau(pS422) antibodies and methods of use
CN105939722A (zh) * 2014-02-14 2016-09-14 伊皮埃里安股份有限公司 Tau肽，抗Tau抗体，及其使用方法
AR100978A1 (es) * 2014-06-26 2016-11-16 Hoffmann La Roche LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
TWI664190B (zh) 2014-06-27 2019-07-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗－ｔａｕ抗體
JO3576B1 (ar) 2015-02-26 2020-07-05 Lilly Co Eli أجسام مضادة لـ tau واستخداماتها
US10017476B2 (en) 2015-03-16 2018-07-10 Inserm (Institut National De La Sante Et De La Recherche Medicale) 1,4-bis(3-aminopropyl)piperazine derivative and its use
UA126272C2 (uk) * 2015-06-05 2022-09-14 Дженентек, Інк. Антитіло проти тау-білка та спосіб його застосування
WO2016201434A2 (en) * 2015-06-12 2016-12-15 C2N Diagnostics, Llc Stable formulations of humanized anti-tau antibody
CA2989400A1 (en) 2015-06-15 2016-12-22 Angiochem Inc. Ang1005 for the treatment of leptomeningeal carcinomatosis
CN113929779B (zh) 2015-06-24 2025-02-25 豪夫迈·罗氏有限公司 人源化的抗-Tau(pS422)抗体和使用方法
MA41670A1 (fr) * 2015-07-06 2018-05-31 Ucb Biopharma Sprl Anticorps se liant a tau
TN2017000543A1 (en) 2015-07-06 2019-04-12 Ucb Biopharma Sprl Tau-binding antibodies
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
WO2017027691A1 (en) * 2015-08-13 2017-02-16 New York University Antibody-based molecules selective for the {p}ser404 epitope of tau and their uses in the diagnosis and treatment of tauopathy
DK3452507T3 (da) 2016-05-02 2022-11-14 Prothena Biosciences Ltd Tau-immunoterapi
SG11201808434WA (en) 2016-05-02 2018-10-30 Prothena Biosciences Ltd Antibodies recognizing tau
CU24538B1 (es) 2016-05-02 2021-08-06 Prothena Biosciences Ltd Anticuerpos monoclonales que compiten por unirse a tau humano con el anticuerpo 16g7
NZ748983A (en) 2016-07-12 2022-12-23 H Lundbeck As Antibodies specific for hyperphosphorylated tau and methods of use thereof
EP3487524A4 (en) * 2016-07-20 2020-03-25 Anahit Ghochikyan HUMANIZED ANTI-TAU ANTIBODIES, COMPOSITIONS AND MANUFACTURING METHODS AND METHODS OF USE IN THE TREATMENT, DIAGNOSIS AND MONITORING OF TAUOPATHIES
JP7019201B2 (ja) * 2016-08-02 2022-02-15 キュリアールエックス インコーポレーテッド リポソームの調製方法
CA3032692A1 (en) 2016-08-09 2018-02-15 Eli Lilly And Company Combination antibody therapy for the treatment of neurodegenerative diseases
MX2019006334A (es) * 2016-12-07 2019-08-01 Genentech Inc Anticuerpos antitau y métodos de uso.
CA3045294A1 (en) 2016-12-07 2018-06-14 Genentech, Inc. Anti-tau antibodies and methods of use
JP2020508054A (ja) 2017-02-17 2020-03-19 デナリ セラピューティクス インコーポレイテッドＤｅｎａｌｉ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 抗タウ抗体及びその使用方法
JP2018139530A (ja) 2017-02-27 2018-09-13 帝人ファーマ株式会社 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤
EP3601337A1 (en) 2017-03-28 2020-02-05 Genentech, Inc. Methods of treating neurodegenerative diseases
BR112019022906A2 (pt) 2017-05-02 2020-05-26 Prothena Biosciences Limited Anticorpos que reconhecem tau
JP2020529394A (ja) * 2017-06-16 2020-10-08 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ タウオパチーを治療するための組成物及び方法
UA129617C2 (uk) 2017-10-16 2025-06-18 Еісаі Р Енд Д Менеджмент Ко., Лтд. Антитіло до тау та його застосування
CN108103027B (zh) * 2018-02-02 2021-12-24 中国医学科学院血液病医院（血液学研究所） 高效率血细胞重编程同时实现基因编辑的方法
CN121276062A (zh) * 2018-07-19 2026-01-06 吉宁特有限公司 基于标志物分子鉴定个体具有淀粉样蛋白阳性痴呆症或处于其发展风险中的方法和用途
EP3829634A1 (en) 2018-07-31 2021-06-09 Eli Lilly and Company Combination therapy
KR20210111242A (ko) 2018-10-29 2021-09-10 바이오젠 엠에이 인코포레이티드 혈액 뇌 장벽 수송을 향상시키기 위한 인간화 및 안정화된 fc5 변이체
WO2020096608A1 (en) * 2018-11-08 2020-05-14 Prothena Biosciences Limited Antibodies recognizing tau
KR20250130862A (ko) 2019-01-22 2025-09-02 클렘손 유니버서티 리서치 화운데이션 항-엘라스틴 항체 및 사용 방법
CA3131531A1 (en) 2019-03-03 2020-09-10 Prothena Biosciences Limited Antibodies recognizing tau
JP7181438B2 (ja) 2019-08-06 2022-11-30 アプリノイア セラピューティクス リミテッド 病理学的タウ種に結合する抗体及びその使用
AU2020397508A1 (en) * 2019-12-05 2022-06-09 Axoltis Pharma Peptide compositions and methods for treating Tauopathies
EP4135841A1 (en) 2020-04-15 2023-02-22 Voyager Therapeutics, Inc. Tau binding compounds
US20230265175A1 (en) 2020-06-25 2023-08-24 Merck Sharp & Dohme Llc High affinity antibodies targeting tau phosphorylated at serine 413
WO2022093923A1 (en) * 2020-10-30 2022-05-05 Rush University Medical Center Intranasal immunotherapy for the treatment of alzheimer's disease
AU2021403010A1 (en) 2020-12-16 2023-07-13 Voyager Therapeutics, Inc. Tau binding compounds
WO2022174026A1 (en) * 2021-02-14 2022-08-18 Prothena Biosciences Limited Methods of using antibodies recognizing tau
CL2021001380A1 (es) 2021-05-26 2022-01-14 Corporacion Centro Int De Biomedicina Icc Generación de un nuevo anticuerpo monoclonal sitio específico para la proteína tau y su uso como herramienta en biomarcadores específicos para la detección temprana de enfermedades neurodegenerativas y patologías involucradas con la proteína tau como alzheimer y otras demencias.
MX2024002295A (es) 2021-08-27 2024-03-07 Genentech Inc Metodos para tratar las patologias de tau.
KR20240067082A (ko) 2021-09-09 2024-05-16 알즈패스, 인크. 포스포-타우 항체 및 사용 방법
WO2023081194A2 (en) * 2021-11-03 2023-05-11 Biogen Ma Inc. Methods for treating alzheimer's disease
US20250034559A1 (en) 2021-11-17 2025-01-30 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
US12337309B2 (en) 2022-03-07 2025-06-24 Pavel Kudryavtsev Method of manufacturing inorganic ion exchanger for the selective extraction of lithium from lithium-containing natural and technological brines
US12350658B2 (en) 2022-03-07 2025-07-08 Pavel Kudryavtsev Inorganic ion-exchanger for selective extraction of lithium from lithium-containing natural and industrial brines
KR20240162497A (ko) 2022-03-14 2024-11-15 제넨테크, 인크. 음성 분석에 기반한 신경퇴행성 질환 예측
EP4544544A1 (en) 2022-06-21 2025-04-30 Genentech Inc. Detecting longitudinal progression of alzheimer's disease (ad) based on speech analyses
WO2023250388A1 (en) 2022-06-22 2023-12-28 Voyager Therapeutics, Inc. Tau binding compounds
KR20250069606A (ko) 2022-09-15 2025-05-19 보이저 테라퓨틱스, 인크. 타우 결합 화합물
CN116948025B (zh) * 2023-09-14 2024-04-02 北京凯祥弘康生物科技有限公司 一种抗Tau蛋白的抗体
WO2025122634A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
WO2025253337A2 (en) * 2024-06-05 2025-12-11 Sanofi Monospecific and bispecific tau binding proteins and compositions thereof

Family Cites Families (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4866132A (en) 1986-04-17 1989-09-12 The Research Foundation Of State University Of New York Novel radiopaque barium polymer complexes, compositions of matter and articles prepared therefrom
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5811310A (en) 1986-09-30 1998-09-22 Albert Einstein College Of Medicine Of Yeshiva Univ. The Alz-50 monoclonal antibody and diagnostic assay for alzheimer's disease
AU612370B2 (en) 1987-05-21 1991-07-11 Micromet Ag Targeted multifunctional proteins
US5256334A (en) 1988-09-08 1993-10-26 The Research Foundation Of The State University Of New York Homogeneous radiopaque polymer-organobismuth composites
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
EP0600951A4 (en) 1991-08-01 1996-10-30 Paul H Voorheis Diagnostic method for alzheimer's disease.
US5733734A (en) 1991-08-14 1998-03-31 The Trustees Of The University Of Pennsylvania Method of screening for Alzheimer's disease or disease associated with the accumulation of paired helical filaments
AU663725B2 (en) 1991-08-20 1995-10-19 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Adenovirus mediated transfer of genes to the gastrointestinal tract
ATE181571T1 (de) 1991-09-23 1999-07-15 Medical Res Council Methoden zur herstellung humanisierter antikörper
WO1993008302A1 (en) * 1991-10-25 1993-04-29 Itt Automotive Europe Gmbh Monoclonal antibodies directed against the microtubule-associated protein tau
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
JPH07501451A (ja) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
JP2579202Y2 (ja) 1992-04-10 1998-08-20 株式会社小松製作所 圧力補償弁を備えた操作弁
US5600392A (en) 1992-11-25 1997-02-04 Copal Company Limited Position sensor
JPH08503855A (ja) 1992-12-03 1996-04-30 ジェンザイム・コーポレイション 嚢胞性線維症に対する遺伝子治療
JP2879975B2 (ja) 1992-12-14 1999-04-05 エヌ・ブイ・インノジェネティクス・ソシエテ・アノニム 微小管関連タンパク質タウに対するモノクローナル抗体、これらの抗体を分泌するハイブリドーマ、これらのモノクローナル抗体による抗原認識及びこれらの応用
US6010913A (en) 1992-12-14 2000-01-04 N.V. Innogenetics S.A. Isolated human tau peptide
US5346981A (en) 1993-01-13 1994-09-13 Miles Inc. Radiopaque polyurethanes
CA2115811A1 (en) 1993-02-17 1994-08-18 Claus Krebber A method for in vivo selection of ligand-binding proteins
ES2249761T3 (es) 1993-06-24 2006-04-01 Advec Inc. Vectores de adenovirus para terapia genica.
SK283703B6 (sk) 1993-10-25 2003-12-02 Canji, Inc. Rekombinantný adenovírusový vektor a jeho použitie
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
AU698383B2 (en) 1993-12-21 1998-10-29 Innogenetics N.V. Monoclonal antibodies specific for PHF-TAU, hybridomas secreting them, antigen recognition by these antibodies and their applications
ATE234324T1 (de) 1994-07-29 2003-03-15 Innogenetics Nv Monoklonale antikörper gegen ein epitop einer gewissen unterklasse oder form von phosphoryliertem tau, hybridome die diese sezernieren,antigenerkennung durch diese antikörper und deren verwendung
US5625048A (en) 1994-11-10 1997-04-29 The Regents Of The University Of California Modified green fluorescent proteins
US7427392B1 (en) 1994-11-14 2008-09-23 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
KR100551104B1 (ko) 1994-12-09 2006-02-09 임페리얼 컬리지 이노베이션스 리미티드 유전자의 동정
AU4188196A (en) 1994-12-22 1996-07-10 Nissan Chemical Industries Ltd. Organobismuth derivatives and process for producing the same
US5958713A (en) 1995-01-31 1999-09-28 Novo Nordisk A/S Method of detecting biologically active substances by using green fluorescent protein
US5670477A (en) 1995-04-20 1997-09-23 Joseph F. Poduslo Method to enhance permeability of the blood/brain blood/nerve bariers to therapeutic agents
US5968738A (en) 1995-12-06 1999-10-19 The Board Of Trustees Of The Leland Stanford Junior University Two-reporter FACS analysis of mammalian cells using green fluorescent proteins
US6020192A (en) 1996-01-18 2000-02-01 University Of Florida Humanized green fluorescent protein genes and methods
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
JP4162267B2 (ja) 1996-08-27 2008-10-08 カイロン コーポレイション Ｎｅｉｓｓｅｒｉａ ｍｅｎｉｎｇｉｔｉｄｉｓ血清型Ｂ複合糖質およびその使用法
US5976796A (en) 1996-10-04 1999-11-02 Loma Linda University Construction and expression of renilla luciferase and green fluorescent protein fusion genes
TW371617B (en) 1996-10-09 1999-10-11 Of Animal And Plant Health Inspection And Quarantine Council Of Agriculture Executive Yuan Bureau Method to transplant GFP into autographa californica multiple nuclear polyhedrosis virus for inflicting pest in an attempt to detect and flow up it existence and to improve life span against UV
WO1998022120A1 (en) 1996-11-19 1998-05-28 The Wistar Institute Of Anatomy & Biology Diagnostic and therapeutic reagents for alzheimer's disease
US6080849A (en) 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
AR014621A1 (es) 1997-12-12 2001-03-28 Macromed Inc Un poli (etilenglicol) con forma de estrella, heterofuncional, biocompatible, metodo para su obtencion y metodo para conjugarlo con una proteina
US20040014142A1 (en) 1998-07-03 2004-01-22 Innogenetics N.V. Differential diagnosis of neurodegeneration
US5985577A (en) 1998-10-14 1999-11-16 The Trustees Of Columbia University In The City Of New York Protein conjugates containing multimers of green fluorescent protein
AU6234700A (en) 1999-07-27 2001-02-13 Abgenix, Inc. Methods and compositions for inhibiting polypeptide accumulation associated with neurological disorders
CA2397991C (en) 2000-01-24 2017-10-24 Innogenetics N.V. Diagnosis of tauopathies
DE60141752D1 (de) 2000-06-30 2010-05-20 Innogenetics Nv Differentielle diagnose von neurologischen krankheiten
AU2001273361A1 (en) 2000-07-11 2002-01-21 Molecular Geriatrics Corporation Reagents and methods for identification of binding agents
AU2002222139A1 (en) * 2000-12-09 2002-06-18 Cambridge University Technical Services Limited Hcv vaccines
US7466180B2 (en) 2000-12-12 2008-12-16 Intel Corporation Clock network
GB0101049D0 (en) 2001-01-15 2001-02-28 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
AT500379B8 (de) 2001-02-02 2009-08-15 Axon Neuroscience Tau-proteine
GB0105924D0 (en) 2001-03-09 2001-04-25 Microscience Ltd Promoter
AU2002314794A1 (en) 2001-05-23 2002-12-03 New York University Detection of alzheimer's amyloid by magnetic resonance imaging
GB0117326D0 (en) 2001-07-16 2001-09-05 Univ Aberdeen Napthoquinone-type inhibitors of protein aggregation
AU2002355477B2 (en) 2001-08-03 2008-09-25 Medical Research Council Method of identifying a consensus sequence for intracellular antibodies
IL160701A0 (en) 2001-09-21 2004-08-31 Mitsubishi Pharma Corp 3-substituted-4-pyrimidone derivatives
AU2003253014A1 (en) 2002-06-21 2004-01-06 Innogenetics N.V. Method for the diagnosis and differential diagnosis of neurological diseases
AU2003253044B2 (en) 2002-07-12 2009-08-13 Axon Neuroscience Se Truncated tau proteins
US7250551B2 (en) 2002-07-24 2007-07-31 President And Fellows Of Harvard College Transgenic mice expressing inducible human p25
WO2004016655A1 (ja) 2002-08-14 2004-02-26 Mitsubishi Chemical Corporation 中枢性タウ蛋白質特異的抗体
EP1480041A1 (en) 2003-05-22 2004-11-24 Innogenetics N.V. Method for the prediction, diagnosis and differential diagnosis of Alzheimer's disease
ES2424353T3 (es) 2003-07-08 2013-10-01 Genentech, Inc. Polipéptidos heterólogos IL-17 A/F y usos terapéuticos de los mismos
US20050261475A1 (en) 2004-02-13 2005-11-24 Harvard Medical School Solid-phase capture-release-tag methods for phosphoproteomic analyses
US7238788B2 (en) 2004-02-18 2007-07-03 University Of Iowa Foundation Antibodies to phosphorylated tau, methods of making and methods of use
WO2005080594A2 (en) 2004-02-24 2005-09-01 Innogenetics N.V. Method for determining the risk of developing a neurological disease
JP4885122B2 (ja) 2004-04-15 2012-02-29 ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド 癌、器官傷害、および筋肉リハビリテーション／運動過剰訓練についての診断の生物マーカーとしてのタンパク質分解マーカー
CA2570458C (en) * 2004-06-09 2014-05-20 Technion Research & Development Foundation Ltd. Antibodies for selective apoptosis of cells
KR101699142B1 (ko) 2004-06-18 2017-01-23 암브룩스, 인코포레이티드 신규 항원-결합 폴리펩티드 및 이의 용도
CN1721437A (zh) * 2004-07-13 2006-01-18 中南大学 一种与Tau蛋白相关的多肽抗原及抗体
JP4730584B2 (ja) 2004-12-06 2011-07-20 東亞合成株式会社 抗菌ペプチド及びその利用
US20090016959A1 (en) 2005-02-18 2009-01-15 Richard Beliveau Delivery of antibodies to the central nervous system
US8741260B2 (en) 2005-10-07 2014-06-03 Armagen Technologies, Inc. Fusion proteins for delivery of GDNF to the CNS
EP1772732A1 (en) 2005-10-07 2007-04-11 Innogenetics N.V. Polymer replicated interdigitated electrode arrays for (bio)sensing applications
WO2007068105A1 (en) 2005-12-12 2007-06-21 Robarts Research Institute Method of diagnosing amyotrophic lateral sclerosis
US20070218491A1 (en) 2006-02-08 2007-09-20 Oligomerix, Inc. Oligomerization of amyloid proteins
US20110143380A1 (en) 2006-03-14 2011-06-16 The Washington University Alzheimer's disease biomarkers and methods of use
US8012936B2 (en) 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
US8729225B2 (en) 2006-11-13 2014-05-20 Intrexon Corporation Glycogen synthase kinase heteropolyligand polypeptide
HRP20140049T1 (hr) 2007-01-05 2014-02-28 University Of Zürich Anti beta-amiloid antitijela i njihova upotreba
US20080220449A1 (en) 2007-02-08 2008-09-11 Oligomerix, Inc. Biomarkers and assays for Alzheimer's disease
US8178317B2 (en) 2007-05-01 2012-05-15 Dana-Farber Cancer Institute, Inc. Compositions and methods for identifying transforming and tumor suppressor genes
PE20090329A1 (es) 2007-05-30 2009-03-27 Abbott Lab Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos
CA2697045C (en) 2007-08-21 2019-12-31 Washington University Improved alzheimer's diagnosis
US9370531B2 (en) 2007-08-31 2016-06-21 New York University Method of providing patient specific immune response in amyloidoses and protein aggregation disorders
JP2010538611A (ja) 2007-09-07 2010-12-16 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク タウタンパク質スクリーニングアッセイ
US8506933B2 (en) 2007-11-30 2013-08-13 Msdx, Inc. Methods of detecting a neurological condition via analysis of circulating phagocytes
CA2730737A1 (en) 2008-07-15 2010-01-21 Novartis Ag Immunogenic amphipathic peptide compositions
US20110312059A1 (en) 2008-08-20 2011-12-22 Oligomerix Inc. Tau protease compositions and methods
US9464122B2 (en) 2008-08-20 2016-10-11 Oligomerix, Inc. Methods and compositions comprising tau oligomers
BRPI0923283A2 (pt) 2008-12-05 2017-06-06 Angiochem Inc conjugados terapêuticos de peptídeo e usos dos mesmos
US9605054B2 (en) 2009-02-23 2017-03-28 The Board Of Trustees Of The University Of Illinois Composition and method for treating a tauopathy
UA107571C2 (xx) 2009-04-03 2015-01-26 Фармацевтична композиція
US8409584B2 (en) 2009-05-05 2013-04-02 New York University Immunotherapy targeting of the shared abnormal conformational state of amyloidogenic peptides/proteins
WO2010132453A2 (en) 2009-05-11 2010-11-18 Nexus Dx, Inc. Methods and compositions for analyte detection
US8609097B2 (en) 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
WO2010144711A2 (en) 2009-06-10 2010-12-16 New York University Immunological targeting of pathological tau proteins
IN2012DN00446A (lt) 2009-07-30 2015-05-15 Pfizer Vaccines Llc
CA2772379C (en) 2009-08-28 2019-09-24 Rakez Kayed Antibodies that bind tau oligomers
EA201290194A1 (ru) 2009-11-06 2013-04-30 Дзе Дж. Дейвид Гладстоун Инститьютс Способы и композиции для модулирования уровня тау-полипептида
EP3527220A1 (en) 2010-08-12 2019-08-21 AC Immune S.A. Vaccine engineering
EP2625198B1 (en) 2010-10-07 2015-07-22 AC Immune S.A. Antibodies recognising phospho-tau
US8940272B2 (en) 2010-10-11 2015-01-27 University Of Zurich Human anti-tau antibodies
CA2826286C (en) 2011-01-31 2021-09-21 Intellect Neurosciences Inc. Treatment of tauopathies
WO2012126013A2 (en) 2011-03-17 2012-09-20 Minerva Biotechnologies Corporation Method for making pluripotent stem cells
GB201111361D0 (en) 2011-07-04 2011-08-17 Nordic Bioscience As Biochemical markers for neurodegenerative conditions
GB201112056D0 (en) * 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
SG10201912964PA (en) 2011-09-19 2020-02-27 Axon Neuroscience Se Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease
KR102129220B1 (ko) 2011-09-23 2020-07-02 에이씨 이뮨 에스.에이. 백신 요법
CN108034005B (zh) 2011-10-07 2021-06-25 Ac免疫有限公司 识别Tau的磷酸化特异抗体
US20140294724A1 (en) 2011-10-24 2014-10-02 Intellect Neurosciences, Inc. Compositions and methods for treatment of proteinopathies
DK2794654T3 (da) 2011-12-20 2019-08-05 Janssen Biotech Inc Anti-phf-tau-antistoffer og deres anvendelser
EP2834270B1 (en) 2012-04-05 2019-10-30 AC Immune S.A. Humanized tau antibody
SG10201913370PA (en) * 2012-07-03 2020-03-30 Univ Washington Antibodies to tau
SI2885010T1 (sl) 2012-08-16 2020-07-31 Ipierian, Inc. Metode zdravljenja tauopatije
US20140056901A1 (en) 2012-08-21 2014-02-27 The Institute For Molecular Medicine Anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
US20160122421A1 (en) 2013-06-10 2016-05-05 Ipierian, Inc. Methods of treating a tauopathy
EA039554B1 (ru) * 2013-06-10 2022-02-09 АйПИЕРИАН, ИНК. Способ снижения уровней a40 и/или a42 в нервной клетке и/или во внеклеточной жидкости
WO2015081085A2 (en) 2013-11-27 2015-06-04 Ipierian, Inc. Methods of treating a tauopathy
CN105939722A (zh) 2014-02-14 2016-09-14 伊皮埃里安股份有限公司 Tau肽，抗Tau抗体，及其使用方法

Also Published As

Publication number Publication date
RS60080B1 (sr) 2020-05-29
ME03667B (me) 2020-10-20
JP2015532592A (ja) 2015-11-12
HK1208175A1 (en) 2016-02-26
ES2775192T3 (es) 2020-07-24
HRP20200036T1 (hr) 2020-08-21
KR102076384B1 (ko) 2020-02-11
EP2885010A4 (en) 2016-06-08
GB2507207A (en) 2014-04-23
HUE048780T2 (hu) 2020-09-28
US8926974B2 (en) 2015-01-06
WO2014028777A3 (en) 2014-05-08
US9567395B2 (en) 2017-02-14
US20170174755A1 (en) 2017-06-22
CL2015000352A1 (es) 2015-11-13
PH12015500196B1 (en) 2015-04-06
CY1123515T1 (el) 2022-03-24
MX359817B (es) 2018-10-11
US20190169275A1 (en) 2019-06-06
SI2885010T1 (sl) 2020-07-31
EA035976B1 (ru) 2020-09-08
SMT202000180T1 (it) 2020-05-08
US20140099304A1 (en) 2014-04-10
US20140086921A1 (en) 2014-03-27
US10040847B2 (en) 2018-08-07
CA2882034A1 (en) 2014-02-20
SG10201701181XA (en) 2017-04-27
NZ730763A (en) 2018-06-29
US20140099303A1 (en) 2014-04-10
SG11201500888SA (en) 2015-03-30
EP2885010B1 (en) 2020-01-01
PL2885010T3 (pl) 2020-11-16
TN2015000050A1 (en) 2016-06-29
EA202193044A2 (ru) 2022-03-31
CA2882034C (en) 2019-10-29
BR112015003326A2 (pt) 2017-07-04
US20150239963A1 (en) 2015-08-27
IL237153A0 (en) 2015-04-30
EA201590388A1 (ru) 2015-08-31
GB201322812D0 (en) 2014-02-05
DK2885010T3 (da) 2020-02-03
EP2885010A2 (en) 2015-06-24
KR20150042828A (ko) 2015-04-21
JP6290212B2 (ja) 2018-03-07
AU2013302540B2 (en) 2018-02-15
PT2885010T (pt) 2020-03-11
WO2014028777A2 (en) 2014-02-20
PH12015500196A1 (en) 2015-04-06
EP3685854A1 (en) 2020-07-29
CN104736185A (zh) 2015-06-24
MY176838A (en) 2020-08-24
AU2013302540A1 (en) 2015-04-02
PE20150646A1 (es) 2015-05-21
MX2015001601A (es) 2015-09-25
CN104736185B (zh) 2018-03-20
NZ630542A (en) 2017-06-30
IL237153B (en) 2018-05-31

Similar Documents

Publication Publication Date Title
LT2885010T (lt) Tautopatijos gydymo būdai
HUE046790T2 (hu) A rák kezelésének módszerei
HUE053247T2 (hu) Mieloszuppresszió kezelése
HUE048876T2 (hu) Rákos megbetegedések kezelése
PL2739153T3 (pl) Leczenie raka sutka
EP2864360A4 (en) TARGETED THERAPEUTICS
EP2723384A4 (en) TREATMENT OF PROTEINOPATHIES
HUE037048T2 (hu) Eljárások 4-cikloalkiloxibenzolszulfonamidok elõállítására
EP2906208A4 (en) THERAPEUTIC TREATMENT
EP2935545A4 (en) BIORAFFINATION OF RAW TALL OIL
LT3007726T (lt) Tautopatijos gydymo būdai
PT3626270T (pt) Tratamento de doenças cardiovasculares
PL2839230T3 (pl) Instalacja do obróbki obiektów
AR092198A1 (es) Derivados de pirazolopirimidinas
EP2825212A4 (en) Improved sterilization method
IL231092A0 (en) Treatment of rhinitis
EP2858975A4 (en) FBXO3 INHIBITORS
EP2931176A4 (en) Medical sling
HRP20181000T1 (hr) Postupci liječenja stanja povezanih s kosom
EP2789306A4 (en) TREATMENT SYSTEM
PL2780003T3 (pl) Leczenie niedoczynności kory nadnerczy
IL237150A0 (en) Treatment regimens
DK2976101T3 (da) Behandlingsfremgangsmåde
DK2825636T3 (da) Behandling af sædceller
EP2842958A4 (en) NAPHTHOBISTHIADIAZOLDERIVAT